SCHEDULE: RTW Investments Maintains 8.1% Stake in Protagonist Therapeutics

RTW Investments, LP and Roderick Wong, M.D. filed an amended Schedule 13G, disclosing a continued 8.1% beneficial ownership in Protagonist Therapeutics, Inc.

Summary

• RTW Investments, LP and Roderick Wong, M.D. collectively reported beneficial ownership of 5,059,053 shares of Protagonist Therapeutics, Inc. Common Stock.
• This ownership represents 8.1% of the company's outstanding Common Stock.
• The percentage is calculated based on 62,515,666 shares outstanding as of October 29, 2025, as reported in the company's Form 10-Q.
• Both RTW Investments, LP and Roderick Wong, M.D. hold shared voting and shared dispositive power over all 5,059,053 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Protagonist Therapeutics, Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, primarily due to the continued significant institutional backing from a specialized healthcare investor, which can be a sign of confidence. However, as a routine disclosure, it does not introduce new fundamental information to significantly alter the investment thesis.

Positives

• The continued significant stake (8.1%) held by an institutional investor like RTW Investments, LP, a specialized healthcare investment firm, can signal confidence in Protagonist Therapeutics' long-term prospects.
• The filing explicitly states the shares are held in the ordinary course of business and not for influencing control, indicating a passive, supportive investment stance.

Industry Context

StockSavvy.ai notes that institutional ownership is a common and often positive indicator in the biotechnology sector, where long-term investment horizons are typical due to the lengthy drug development cycles. The continued significant stake by RTW Investments, a firm focused on life sciences, suggests ongoing belief in Protagonist Therapeutics' pipeline or market position, aligning with broader trends of specialized funds backing innovative biotech companies.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant institutional investor's continued stake, which can provide a level of stability and confidence in the company's ownership structure.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of an existing significant passive ownership stake. It does not contain new material information regarding the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The continued institutional ownership is a neutral to slightly positive signal, but not enough to alter a seasoned investor's existing thesis on Protagonist Therapeutics.

Keywords

Protagonist Therapeutics, RTW Investments, Roderick Wong, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Healthcare Investment